Key facts
- It has raised $5.2M; the latest was Seed Round ($5.0M) in Jan 2026.
- Notable investors include Innovate UK, Berkeley SkyDeck, AppWorks, Oxford Science Enterprises, Habico Invest — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Allos AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Allos AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allos AI
Developer of a drug reformulation platform intended to prognose, monitor, and treat autoimmune conditions. The company's product analyzes data and identifies the cause-and-effect relationships between variables to help find precise and actionable strategies to tackle complex scenarios, providing patients with accessible and safe drugs.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 15
- Website
- allos.ai/
- Ownership
- Privately Held (backing)
Allos AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allos AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allos AI in its N-PORT filings yet. We sweep new filings monthly.